Food diary
Record eating patterns and binge-eating episodes.
Eating disorders · Prescription digital therapeutic
SerenQ®
Treatment software to improve binge-eating symptoms in patients with eating disorders
Understand eating patterns through an eight-session cognitive behavioral therapy program.
MFDS authorizedNET certification
MFDS authorization 25-346
How it works
Record meals and emotions
Follow the treatment program
Record meals and emotions as you follow eight sessions of cognitive behavioral therapy.
Mood diary
Review thoughts and emotions around meals.
Cognitive behavioral therapy
Follow an eight-session program.
Review progress
Review symptom changes with the clinician.
SerenQ® · Clinical evidence
66% reduction in binge-eating frequency at eight weeks
- Participants
- Patients with eating disorders
- Comparator
- In-person psychiatric care every two weeks
- Assessment
- Week eight
Reduction in binge-eating frequency after eight weeks
These percentages describe changes in episode frequency, not cure or responder rates.
Between-group difference23pp
SerenQ® reduced binge-eating frequency by 23 percentage points more than the in-person care group.
A percentage point (pp) is the unit used for the difference between two percentages.
p = 0.0031Study design and interpretation
- Design
- Multicenter randomized trial at Seoul National University Hospital and Severance Hospital
- Comparator
- In-person psychiatric care every two weeks over eight weeks
- Program and assessment
- Eight-session treatment program; main outcome assessed at week eight
- Long-term follow-up
- Improvement within the SerenQ® group was observed at 12 months. The between-group difference in binge-eating frequency was not statistically significant (p = 0.156).
- Evidence status
- Company clinical-trial summary; authorization-trial publication in preparation
Source: WELT trial summaries (WCTP-ED-B-01 and WCTP-ED-D-01), September 2026. Results apply to the studied conditions.
SerenQ® · BMI ≥25 subgroup analysis
A larger reduction in binge eating
in the BMI ≥25 subgroup
Observed changes in binge-eating frequency after eight weeks of SerenQ® treatment.
Overall treatment groupSerenQ®
66%Higher-BMI subgroupBMI ≥25
Building on this eating-behavior expertise, WELT is pursuing expansion into obesity and metabolic care.
Subgroup interpretation
The BMI ≥25 subgroup is included in the overall treatment group. The 66% and 76% values describe observed reductions; they are not a comparison of independent trial arms or confirmation that treatment efficacy differs by obesity status.
Within the BMI ≥25 subgroup, binge-eating frequency decreased by 76.0% with SerenQ® and 36.9% with in-person care at eight weeks—a difference of 39.1 percentage points.
These are reductions in binge-eating frequency, not body weight or BMI. Current authorization covers improvement of binge-eating symptoms in patients with eating disorders. These subgroup findings from the company clinical trial summary do not demonstrate weight loss or establish authorization for obesity treatment.
Product status
MFDS authorized
Authorization
MFDS 25-346, May 2025 · NET certification, 2026
Platform
DrugOS™ · Cognitive behavioral therapy